Impact of FLT3 mutations and secondary cytogenetic changes on the outcome of patients with newly diagnosed acute promyelocytic leukemia treated with a single agent arsenic trioxide regimen

Mathews, Vikram ; Thomas, Maria ; Srivastava, Vivi M. ; George, Biju ; Srivastava, Alok ; Chandy, Mammen (2007) Impact of FLT3 mutations and secondary cytogenetic changes on the outcome of patients with newly diagnosed acute promyelocytic leukemia treated with a single agent arsenic trioxide regimen Haematologica, 92 (7). pp. 994-995. ISSN 1466-4860

Preview

PDF - Publisher Version
150kB

Official URL: http://haematologica.org/cgi/content/abstract/92/7...

Related URL: http://dx.doi.org/10.3324/haematol.10802

Abstract

Ninety-eight newly diagnosed cases of PML-RARpositive APL were treated with a regimen of single agent ATO. FLT3 activating mutations were seen in 33% and an additional cytogenetic finding was noted in 23.2%. FLT3 activating mutations were significantly associated with a bcr3 PML-RARisoform (p=0.012) and a delay in achieving a molecular remission (p=0.022). Neither FLT3 activating mutations nor secondary cytogenetic changes had an impact on clinical outcome.

Item Type:	Article
Source:	Copyright of this article belongs to European Hematology Association.
Keywords:	Acute Promyelocytic Leukemia; Arsenic Trioxide; FLT3 Mutation; Cytogenetics
ID Code:	5866
Deposited On:	19 Oct 2010 10:25
Last Modified:	16 May 2016 16:18

Repository Staff Only: item control page